In a recent cellular screening, the activation of YAP1 was discovered as a novel mechanism associated with resistance to a triple combination of EGFR, BRAF, and MEK inhibitors (cetuximab, dabrafenib, and trametinib) in cell lines characterized by BRAF mutant CRC [26]. Here, YAP1 is linked to colorectal carcinoma.